Clinical trials: Blood Plasma Therapy
Lymphoma Neoplasms, Myeloma Multiple
Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.
This is a prospective, multicenter, observational cohort study involving patients with hematologic malignancies who are receiving bispecific antibody therapy.
- Conditions
- Lymphoma Neoplasms, Myeloma Multiple, Severe Infection, CMV Reactivation
- Trial name
- NCT07609576
- Where
- 2 sites in Spain
- Volunteers
- 350 people
- Sponsor
- Infanta Leonor University Hospital
Coronavirus
COVID-19 Convalescent Plasma
The purpose of this study is to assess the feasibility of delivering anti-SARS-CoV-2 convalescent plasma to hospitalized patients with severe or life-threatening COVID-19.
- Trial name
- NCT04340050
- Testing
- anti-SARS-CoV-2 convalescent plasma
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Chicago
Atypical Hemolytic Uremic Syndrome
Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)
The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adult patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS).
- Trial name
- aHUS (NCT00838513)
- Testing
- eculizumab
- Where
- 13 sites in Canada, France and 5 more
- Volunteers
- 15 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment
This phase Ib trial studies side effects and best dose of pevonedistat when given together with ixazomib in treating patients with multiple myeloma that has come back or does not respond to treatment.
- Trial name
- NCT03770260
- Testing
- Ixazomib Citrate, Pevonedistat
- Where
- 9 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma
The aim of our study is to confirm the relevance of PET using [68Ga]Ga -PentixaFor ligand, in comparison with FDG, for initial staging and therapeutic evaluation of symptomatic multiple myeloma patients in first line treatment or…
- Trial name
- PentiMyelo (NCT04561492)
- Testing
- [68Ga]Ga-PentixaFor
- Where
- 3 sites in France
- Volunteers
- 45 people
- Sponsor
- Nantes University Hospital
Foot Ulcers, Diabetic
Efficacy of Plasma Rich in Growth Factors (PRGF) in the Treatment of Foot Ulcers in Diabetic Patients With Peripheral Arterial Disease
This study is a randomized clinical trial that compares the effectiveness of Plasma Rich in Growth Factors (PRGF) with conventional treatment for healing foot ulcers in diabetic patients who also have peripheral arterial disease.
- Trial name
- PIEDIABETICO (NCT06952998)
- Testing
- Topical application of Plasma Rich in Growth Factors (PRGF), Conventional treatment (conventional treatment with adequate offloading and metabolic control, +/- antibiotic).
- Where
- Spain
- Volunteers
- 38 people
- Sponsor
- Biotechnology Institute IMASD
Wrinkles, Acne Scars
Fractional Ablative Radiofrequency for the Treatment of Acne Scars and Wrinkles
To assess the safety and efficacy of the Pixel RF (fractional radio frequency) module in the treatment of acne scars and wrinkles.
- Trial name
- NCT01645345
- Testing
- Alma Lasers Accent RF Pixel handpiece
- Where
- 3 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Alma Lasers Inc.
Acute Myeloid Leukemia, Multiple Myeloma
Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma
The purpose of this first-in-man Phase I-IIa study is to evaluate the safety and antitumor activity of autologous CD44v6 CAR T-cells in patients with acute myeloid leukemia (AML) and multiple myeloma (MM).
- Trial name
- NCT04097301
- Testing
- MLM-CAR44.1 T-cells at day 0 Single intravenous infusion
- Where
- 3 sites in Czechia, Italy
- Volunteers
- 8 people
- Sponsor
- AGC Biologics S.p.A.
Non-hodgkin Lymphoma, Multiple Myeloma
A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy
The purpose of this study is to collect voice recordings and nervous system (neurologic) assessments from people with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) who are receiving standard treatment with CAR T-cell…
- Trial name
- NCT07249528
- Testing
- Audio Tasks
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Wound, Wound Infection
Plasma Activated Saline in Wound Treatment
This is a prospective, open-label, randomized, parallel controlled clinical trial. The purpose of this study is to understand the application value of plasma-activated normal saline in the treatment of different types of wounds.
- Conditions
- Wound, Wound Infection, Wound Heal
- Trial name
- NCT05924867
- Testing
- plasma activated saline, Routine nursing
- Where
- China
- Volunteers
- 162 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Venous Thromboembolism
Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs
Interventional, no-randomized, open-label, and single arm multicentre study of apixaban for the prevention of thromboembolic events during induction therapy in transplant-eligible patients with newly diagnosed multiple myeloma…
- Trial name
- NCT04106700
- Testing
- Apixaban 2.5 MG
- Where
- 4 sites in Spain
- Volunteers
- 60 people
- Sponsor
- Instituto de Investigacion Sanitaria La Fe
Verruca Vulgaris, Molluscum Contagiosum
Cold Atmospheric Plasma Device Extension Study
Patients between 4-21 years of age with at least one wart or molluscum lesion are eligible to participate in this study. The duration of the study is a minimum of 4 weeks with the maximum duration of monthly treatments for one…
- Trial name
- NCT05937672
- Testing
- Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Medical University of South Carolina
Multiple Myeloma
Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support
This study evaluates induction therapy with carfilzomib-cyclophosphamide-dexamethasone before salvage high-dose melphalan with autologous stem cell support (HDT) in multiple myeloma patients with relapse after HDT done at…
- Trial name
- CARFI (NCT02572492)
- Testing
- Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan, Carfilzomib/dexamethasone maintenance, Observation without carfilzomib/dexamethasone maintenance
- Where
- 5 sites in Denmark, Finland and 3 more
- Volunteers
- 200 people
- Sponsor
- Henrik Gregersen
Multiple Myeloma
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
The purpose of this study is to see if the quality of T cells used to create ide-cel (bb2121) affects how ide-cel prevents cancer from coming back in people with relapsed or refractory multiple myeloma (MM), and who have had a…
- Trial name
- NCT05393804
- Testing
- Ide-cel (bb2121)
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
DPMAS Therapy in Liver Disease Patients
Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study)
Acute-on-chronic liver failure (ACLF) is a life-threatening syndrome occurring in patients with chronic liver disease. In China, hepatitis B virus (HBV) is the main cause of cirrhosis.
- Trial name
- PADSTONE (NCT05129904)
- Testing
- Double plasma molecular absorption system
- Where
- 56 sites in China
- Volunteers
- 1,300 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Diabetic Foot Ulcers, Diabetic Wound
The Effect of Platelet-Rich Plasma-Fibrin Glue in Combination With Vitamin E and C for Treatment of Non-healing Diabetic Foot Ulcers
The aim of this study is to evaluates the chance of non-healing Diabetic Foot Ulcers repair by reducing oxidative stress caused by diabetes by taking vitamin E and C supplements along with the use of Platelet-Rich Plasma-Fibrin…
- Trial name
- NCT04315909
- Testing
- PRP-Fibrin Glue, Vitamin E and C
- Where
- Iran
- Volunteers
- 24 people
- Sponsor
- Mashhad University of Medical Sciences
Cold Argon Plasma
Cold Argon Plasma (CAP) Application in the Wound Treatment After Open Hemorrhoidectomy
This is single-center, prospective, randomized study
- Trial name
- NCT03907306
- Testing
- Wound healing
- Where
- Russia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- State Scientific Centre of Coloproctology, Russian Federation
Multiple Myeloma
QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression
The primary objective is to evaluate when Revlimid and Dexamethasone treatment extend the time to progression to symptomatic MM in patients with smoldering MM.
- Trial name
- QUIREDEX (NCT00480363)
- Testing
- Maintenance with lower doses of lenalidomide and dexamethasone
- Where
- 13 sites in Spain
- Volunteers
- 120 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of NOX A12 alone and in combination with a background therapy of bortezomib and dexamethasone (VD) chemotherapy in previously treated patients with multiple myeloma…
- Trial name
- NCT01521533
- Testing
- NOX-A12
- Where
- 10 sites in Austria, France and 2 more
- Volunteers
- 28 people
- Sponsor
- TME Pharma AG
Relapsed or Refractory Multiple Myeloma (RRMM)
Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
This is a multicenter, open-label, non-randomized, single-arm clinical trial. Patients with relapsed/refractory multiple myeloma accompanied by extramedullary infiltration will receive BCMA - CD19 CAR-T cell therapy.
- Trial name
- NCT07003555
- Testing
- Dual-targeting BCMA-CD19 CAR-T cell infusion
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Beijing GoBroad Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.